{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:29:51Z","timestamp":1793644191433,"version":"4.5.1"},"reference-count":104,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Therapeutic T-cell engineering is emerging as a powerful approach to treat refractory hematological malignancies. Its most successful embodiment to date is based on the use of second-generation chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule found in most B-cell leukemias and lymphomas. Remarkable complete remissions have been obtained with autologous T cells expressing CD19 CARs in patients with relapsed, chemo-refractory B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. Allogeneic CAR T cells may also be harnessed to treat relapse after allogeneic hematopoietic stem cell transplantation. However, the use of donor T cells poses unique challenges owing to potential alloreactivity. We review different approaches to mitigate the risk of causing or aggravating graft-versus-host disease (GVHD), including CAR therapies based on donor leukocyte infusion, virus-specific T cells, T-cell receptor\u2013deficient T cells, lymphoid progenitor cells, and regulatory T cells. Advances in CAR design, T-cell selection and gene editing are poised to enable the safe use of allogeneic CAR T cells without incurring GVHD.<\/jats:p>","DOI":"10.1182\/blood-2017-08-752121","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T15:25:18Z","timestamp":1516634718000},"page":"1045-1052","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":84,"title":["Posttransplant chimeric antigen receptor therapy"],"prefix":"10.1182","volume":"131","author":[{"given":"Melody","family":"Smith","sequence":"first","affiliation":[{"name":"Center for Cell Engineering and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Zakrzewski","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"James","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-6430","authenticated-orcid":false,"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111904330821700_B1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1083-8791(99)70010-8","article-title":"Historical markers in the development of allogeneic hematopoietic cell transplantation","volume":"5","author":"Thomas","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"2019111904330821700_B2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111904330821700_B3","article-title":"One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511-533","author":"Thomas"},{"issue":"22","key":"2019111904330821700_B4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease-biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"2019111904330821700_B5","first-page":"371","article-title":"T cell depletion for the prevention of graft-vs-host disease","author":"Martin","year":"1990"},{"issue":"12","key":"2019111904330821700_B6","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood.V98.12.3192","article-title":"The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Ho","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2019111904330821700_B7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2010.04.004","article-title":"NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation","volume":"16","author":"Pavletic","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1 Suppl","key":"2019111904330821700_B8","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.bbmt.2009.10.023","article-title":"Relapse after allogeneic hematopoietic cell therapy","volume":"16","author":"van den Brink","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111904330821700_B9","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"2","key":"2019111904330821700_B10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111904330821700_B11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.hemonc.2017.05.002","article-title":"Reduced-intensity versus myeloablative allogeneic transplantation","volume":"10","author":"Weisdorf","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"7655","key":"2019111904330821700_B12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"issue":"3","key":"2019111904330821700_B13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"issue":"9","key":"2019111904330821700_B14","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"issue":"95","key":"2019111904330821700_B15","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"18","key":"2019111904330821700_B16","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111904330821700_B17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"177","key":"2019111904330821700_B18","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"16","key":"2019111904330821700_B19","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"224","key":"2019111904330821700_B20","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"16","key":"2019111904330821700_B21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111904330821700_B22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9967","key":"2019111904330821700_B23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"303","key":"2019111904330821700_B24","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2019111904330821700_B25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/asheducation-2014.1.570","article-title":"Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions","volume":"2014","author":"Nikiforow","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2019111904330821700_B26","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"issue":"1","key":"2019111904330821700_B27","first-page":"12","article-title":"Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant","volume":"4","author":"Porter","year":"1994","journal-title":"Transplant Sci"},{"issue":"5","key":"2019111904330821700_B28","first-page":"975","article-title":"Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation","volume":"18","author":"Porter","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111904330821700_B29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14712598.2011.554811","article-title":"Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Roddie","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"2019111904330821700_B30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beha.2008.02.007","article-title":"Graft-versus-host disease after donor leukocyte infusions: presentation and management","volume":"21","author":"Frey","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"25","key":"2019111904330821700_B31","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111904330821700_B32","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111904330821700_B33","doi-asserted-by":"crossref","first-page":"e1027469","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"OncoImmunology"},{"issue":"9","key":"2019111904330821700_B34","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111904330821700_B35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"issue":"4","key":"2019111904330821700_B36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111904330821700_B37","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells [published correction appears in Immunity. 2016;44(3):712]","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"10","key":"2019111904330821700_B38","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","article-title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","volume":"127","author":"Jacoby","year":"2016","journal-title":"Blood"},{"key":"2019111904330821700_B39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Jae","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111904330821700_B40","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"24","key":"2019111904330821700_B41","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2019111904330821700_B42","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5067","key":"2019111904330821700_B43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"issue":"17","key":"2019111904330821700_B44","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111904330821700_B45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJM199409083311017","article-title":"Donor T cells to treat EBV-associated lymphoma","volume":"331","author":"Heslop","year":"1994","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111904330821700_B46","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111904330821700_B47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbmt.2003.09.017","article-title":"Adoptive immunotherapy for posttransplantation viral infections","volume":"10","author":"Bollard","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2019111904330821700_B48","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111904330821700_B49","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J Immunother"},{"issue":"1","key":"2019111904330821700_B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190400002202","article-title":"Adoptive immunotherapy for EBV-associated malignancies","volume":"46","author":"Gottschalk","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111904330821700_B51","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111904330821700_B52","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111904330821700_B53","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111904330821700_B54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","article-title":"Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells","volume":"119","author":"Terakura","year":"2012","journal-title":"Blood"},{"issue":"17","key":"2019111904330821700_B55","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111904330821700_B56","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nm.2700","article-title":"Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer","volume":"18","author":"Provasi","year":"2012","journal-title":"Nat Med"},{"issue":"24","key":"2019111904330821700_B57","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR [published correction appears in Blood. 2015;126(22):2527]","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111904330821700_B58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/gt.2014.26","article-title":"TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer","volume":"21","author":"Berdien","year":"2014","journal-title":"Gene Ther"},{"key":"2019111904330821700_B59","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","author":"Poirot","year":"2015"},{"issue":"7643","key":"2019111904330821700_B60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"1","key":"2019111904330821700_B61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6213","key":"2019111904330821700_B62","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"5","key":"2019111904330821700_B63","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ymthe.2017.03.034","article-title":"Chimeric antigen receptors: a cell and gene therapy perspective","volume":"25","author":"Rivi\u00e8re","year":"2017","journal-title":"Mol Ther"},{"issue":"374","key":"2019111904330821700_B64","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"issue":"6","key":"2019111904330821700_B65","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1074-7613(02)00474-0","article-title":"Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro","volume":"17","author":"Schmitt","year":"2002","journal-title":"Immunity"},{"issue":"1","key":"2019111904330821700_B66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nri1257","article-title":"T-cell development made simple","volume":"4","author":"Z\u00fa\u00f1iga-Pfl\u00fccker","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2019111904330821700_B67","first-page":"979","article-title":"Involvement of the c-kit receptor in the adhesion of hematopoietic stem cells to stromal cells","volume":"22","author":"Kodama","year":"1994","journal-title":"Exp Hematol"},{"issue":"3","key":"2019111904330821700_B68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.bcmd.2004.08.007","article-title":"Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment","volume":"33","author":"De Smedt","year":"2004","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"2019111904330821700_B69","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood-2004-04-1293","article-title":"Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro","volume":"105","author":"La Motte-Mohs","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111904330821700_B70","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2008-10-187013","article-title":"Characterization in vitro and engraftment potential in vivo of human progenitor T cells generated from hematopoietic stem cells","volume":"114","author":"Awong","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111904330821700_B71","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3324\/haematol.2010.036343","article-title":"T-lymphoid differentiation potential measured in vitro is higher in CD34+CD38-\/lo hematopoietic stem cells from umbilical cord blood than from bone marrow and is an intrinsic property of the cells","volume":"96","author":"De Smedt","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111904330821700_B72","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"10","key":"2019111904330821700_B73","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2019111904330821700_B74","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nmeth.4258","article-title":"Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1","volume":"14","author":"Shukla","year":"2017","journal-title":"Nat Methods"},{"issue":"8","key":"2019111904330821700_B75","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1182\/blood-2006-08-039842","article-title":"Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1","volume":"109","author":"Dallas","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2019111904330821700_B76","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/stem.1145","article-title":"Human T-lymphoid progenitors generated in a feeder-cell-free Delta-like-4 culture system promote T-cell reconstitution in NOD\/SCID\/\u03b3c(-\/-) mice","volume":"30","author":"Reimann","year":"2012","journal-title":"Stem Cells"},{"issue":"9","key":"2019111904330821700_B77","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nm1463","article-title":"Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Zakrzewski","year":"2006","journal-title":"Nat Med"},{"issue":"4","key":"2019111904330821700_B78","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nbt1395","article-title":"Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors","volume":"26","author":"Zakrzewski","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2019111904330821700_B79","first-page":"157","article-title":"Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras","volume":"119","author":"Papapetrou","year":"2009","journal-title":"J Clin Invest"},{"issue":"26","key":"2019111904330821700_B80","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1182\/blood-2012-12-472803","article-title":"Human proT-cells generated in vitro facilitate hematopoietic stem cell-derived T-lymphopoiesis in vivo and restore thymic architecture","volume":"122","author":"Awong","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111904330821700_B81","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1172\/JCI60630","article-title":"Extrathymic development of murine T cells after bone marrow transplantation","volume":"122","author":"Holland","year":"2012","journal-title":"J Clin Invest"},{"key":"2019111904330821700_B82","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fimmu.2013.00163","article-title":"The role of regulatory T cells in the biology of graft versus host disease","volume":"4","author":"Beres","year":"2013","journal-title":"Front Immunol"},{"issue":"9","key":"2019111904330821700_B83","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/2326-6066.CIR-16-0193","article-title":"Regulatory T cells: differentiation and function","volume":"4","author":"Plitas","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"5609","key":"2019111904330821700_B84","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"issue":"4","key":"2019111904330821700_B85","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"issue":"11","key":"2019111904330821700_B86","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1084\/jem.193.11.1311","article-title":"CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade","volume":"193","author":"Taylor","year":"2001","journal-title":"J Exp Med"},{"issue":"3","key":"2019111904330821700_B87","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.20020399","article-title":"Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"196","author":"Hoffmann","year":"2002","journal-title":"J Exp Med"},{"issue":"9","key":"2019111904330821700_B88","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"issue":"11","key":"2019111904330821700_B89","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI17702","article-title":"Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia","volume":"112","author":"Trenado","year":"2003","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111904330821700_B90","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.leukres.2009.11.024","article-title":"Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation","volume":"34","author":"Cao","year":"2010","journal-title":"Leuk Res"},{"issue":"4","key":"2019111904330821700_B91","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"key":"2019111904330821700_B92","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile and clinical effect","author":"Brunstein","year":"2016"},{"issue":"3","key":"2019111904330821700_B93","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.167.3.1245","article-title":"CD4+CD25high regulatory cells in human peripheral blood","volume":"167","author":"Baecher-Allan","year":"2001","journal-title":"J Immunol"},{"issue":"9","key":"2019111904330821700_B94","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/eji.200526077","article-title":"Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation","volume":"35","author":"Albert","year":"2005","journal-title":"Eur J Immunol"},{"issue":"1","key":"2019111904330821700_B95","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4049\/jimmunol.1402861","article-title":"Donor requirements for regulatory T cell suppression of murine graft-versus-host disease","volume":"195","author":"Pierini","year":"2015","journal-title":"J Immunol"},{"issue":"7","key":"2019111904330821700_B96","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"2019111904330821700_B97","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"2019111904330821700_B98","author":"Yoon","year":"2016"},{"issue":"2","key":"2019111904330821700_B99","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1042\/BST20150247","article-title":"Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?","volume":"44","author":"Boardman","year":"2016","journal-title":"Biochem Soc Trans"},{"issue":"8","key":"2019111904330821700_B100","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","article-title":"In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"2019111904330821700_B101","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111904330821700_B102","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/gt.2009.75","article-title":"Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity","volume":"16","author":"Hombach","year":"2009","journal-title":"Gene Ther"},{"key":"2019111904330821700_B103","doi-asserted-by":"crossref","DOI":"10.1007\/s40778-017-0077-5","article-title":"Genome-edited T cell therapies","author":"Delhove","year":"2017"},{"issue":"4","key":"2019111904330821700_B104","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","article-title":"New cell sources for T cell engineering and adoptive immunotherapy","volume":"16","author":"Themeli","year":"2015","journal-title":"Cell Stem Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/10\/1045\/1405453\/blood752121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/10\/1045\/1405453\/blood752121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:34:02Z","timestamp":1574138042000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/10\/1045\/36415\/Posttransplant-chimeric-antigen-receptor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":104,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,3,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-08-752121","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,8]]}}}